Antitumor activity of (2E,5Z)-5-(2-Hydroxybenzylidene)-2-((4-phenoxyphenyl) imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model

Journal of Pharmacological Sciences

Volumn 122, Issue 3, 2013, Pages 223-231

  Zhang, Qiu ^a   Liu, Xiaojun ^a   Li, Xiue ^a   Li, Changlong ^b   Zhou, Hongyu ^b   Yan, Bing ^a  

^a SHANDONG UNIVERSITY   (China)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Glioblastoma; Microtubule; Microtubule depolymerizing agent; Thiazolidinone; U87MG human glioblastoma cell

Indexed keywords

5 (2 HYDROXYBENZYLIDENE) 2 [[4 PHENOXYPHENYL]IMINO]THIAZOLIDIN 4 ONE; ALCOHOL; COLCHICINE; CREMOPHOR; DIMETHYL SULFOXIDE; TEMOZOLOMIDE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL LINE; CELL STRAIN U87MG; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG STRUCTURE; DRUG TOXICITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; LETHALITY; MICROTUBULE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CELL PROLIFERATION; DACARBAZINE; DISEASE MODELS, ANIMAL; G2 PHASE CELL CYCLE CHECKPOINTS; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULES; NEOPLASM TRANSPLANTATION; PHENYL ETHERS; THIAZOLIDINES; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 84880815848     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13064FP     Document Type: Article

References (30)

1. Desai A, Vyas T, Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci. 2008;97: 2745-2756.
2. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24:1253-1265.
3. Bobola MS, Varadarajan S, Smith NW, Goff RD, Kolstoe DD, Blank A, et al. Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin. Clin Cancer Res. 2007;13:612-620.
4. Djedid R, Kiss R, Lefranc F. Targeted therapy of glioblastomas: a 5-year view. Therapy. 2009;6:351-370.
5. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg. 2003;99:1047-1052.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003.
7. Ravizza R, Cereda E, Monti E, Gariboldi MB. The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolo-mide in human glioblastoma cells. Int J Oncol. 2004;25: 1817-1822.
8. Ottanà R, Maccari R, Barreca ML, Bruno G, Rotondo A, Rossi A, et al. 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents. Bioorg Med Chem. 2005;13:4243-4252.
9. Vicini P, Geronikaki A, Anastasia K, Incerti M, Zani F. Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. Bioorg Med Chem. 2006;14:3859-3864.
10. Teraishi F, Wu S, Zhang L, Guo W, Davis JJ, Dong F, et al. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res. 2005;65:6380-6387.
11. Zhou HY, Wu SH, Zhai SM, Liu AF, Sun Y, Li RS, et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem. 2008;51:1242-1251.
12. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-a signaling. Cancer Res. 2007;67:11493.
13. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168:1107-1118.
14. Kim KH, Park J Y, Jung HJ, Kwon HJ. Identification and biological activities of a new antiangiogenic small molecule that suppresses mitochondrial reactive oxygen species. Biochem Biophys Res Commun. 2011;404:541-545.
15. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.
16. Li LW, Zhang Q, Liu AF, Li XE, Zhou HY, Liu Y, et al. Proteome interrogation using nanoprobes to identify targets of a cancer-killing molecule. J Am Chem Soc. 2011;133:6886-6889.
17. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 2003;8:413-450.
18. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086-2095.
19. Kato Y, Holm DA, Okollie B, Artemov D. Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy. Neuro Oncol. 2010;12:71-79.
20. Newlands E, Stevens M, Wedge S, Wheelhouse R, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35-61.
21. Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III b-tubulin. J Cell Physiol. 2009;221: 505-513.
22. Katsetos CD, Dráberová E, Legido A, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. g-tubulin. J Cell Physiol. 2009;221:514-520.
23. Jan ST, Mao C, Vassilev AO, Navara CS, Uckun FM. COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent. Bioorg Med Chem Lett. 2000;10:1193-1197.
24. Yoon JT, Palazzo AF, Xiao D, Delohery TM, Warburton PE, Bruce JN, et al. CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther. 2002;1:393.
25. Beyer CF, Zhang N, Hernandez R, Vitale D, Lucas J, Nguyen T, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008;68:2292.
26. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010;1352:255-264.
27. Gajate C, Barasoain I, Andreu JM, Mollinedo F. Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2′, 3′, 4′-trimethoxyphenyl)-2, 4, 6-cycloheptatrien-1-one: protection by Bcl-2 and Bcl-XL and cell cycle arrest. Cancer Res. 2000;60:2651-2659.
28. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5:689-698.
29. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat. 2007;10:162-181.
30. Lee JJ, Low JA, Croarkin E, Parks R, Berman AW, Mannan N, et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol. 2006;24:2084-2091.